MMSI — Merit Medical Systems, Inc.

Is MMSI overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Oversold As of November 17, 2026

Merit Medical Systems, Inc. (MMSI) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $86.35. The rating moved from Neutral to Oversold on November 12, 2026.

See all oversold Healthcare stocks →

AI analysis

Merit Medical Systems, Inc. (MMSI) is a specialty medical device company with recurring consumable revenue tied to interventional cardiology, radiology and oncology procedures. The company benefits from secular shifts toward specialty-care distribution channels and steady procedure volumes that support predictable cash flows and the ability to invest in product development and targeted acquisitions. Near-term performance will be influenced by elective procedure trends, hospital purchasing dynamics and any supply-chain disruptions. Policy and reimbursement developments could pressure pricing, while competitive pressures from larger medtech firms remain a consideration. Given current market tone focused on policy clarity and defensive flows into healthcare, Merit’s niche product mix and recurring revenue profile provide a favorable backdrop for modest near-term upside, while downside risks remain tied to volumes, pricing and execution.

Key factors

  • Market position in single-use interventional devices and disposables with recurring revenue characteristics
  • Beneficiary of sector trend shifting distributors and specialty channels toward infusion, biopharma services and specialty care
  • Stable procedure-driven demand tied to cardiology, radiology and oncology use cases that can support steady revenue
  • Historically solid operating cash flow profile enabling reinvestment in new products and selective M&A
  • Limited sensitivity to headline biotech volatility relative to pure biopharma names; defensive elements in device consumables

Risks

  • Elective procedure volume declines or broader macro weakness that reduces hospital procedure throughput
  • Reimbursement pressure and pricing compression from payors or hospital purchasing groups
  • Intensifying competition from larger medtech players or lower‑cost offshore suppliers
  • Supply chain disruptions or component shortages that constrain shipments and margins
  • Regulatory and policy risk from heightened antitrust or healthcare reform activity impacting channel or payer dynamics
  • Valuation risk if expectations for continued margin expansion or revenue growth are not met

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for MMSI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.